Novaliq Announces Publication of Second Pivotal Phase 3 Trial Data on CyclASol 0.1% (Cyclosporine Op

HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that results from the second pivotal Phase 3 trial for CyclASol®, ESSENCE-2, have been published in...

Related Keywords

Germany ,Heidelberg ,Baden Wüberg ,Netherlands ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Holland ,American ,Christian Roesky ,Novaliq Gmb ,Drug Administration ,National Eye Institute ,Health Sciences ,Novaliq Inc ,Gmbh Co ,Wilmer Eye Institute Of Johns Hopkins ,Journal Of The American Medical Association ,American Medical Association ,Prescription Drug User Fee Act ,Water Free Topical Cyclosporine ,Severe Dry Eye Disease ,Randomized Clinical ,Esen Akpek ,Wilmer Eye Institute ,Johns Hopkins ,Hopp Biotech ,Lifitegrast Ophthalmic Solution ,Patients With Moderate ,Post Hoc Analysis ,